| 词条 | VNI (molecule) |
| 释义 |
| ImageFile = VNI molecule.svg | ImageSize = 200px | IUPACName = N-[(1R)-1-(2,4-dichlorophenyl)-2-imidazol-1-yl-ethyl]-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide | OtherNames = |Section1={{Chembox Identifiers | CASNo = 1246770-52-4 | CASNo_Ref = {{cascite|correct|}} | PubChem = | ChemSpiderID = 25060282 | SMILES = c1ccc(cc1)c2nnc(o2)c3ccc(cc3)C(=O)N[C@@H](Cn4ccnc4)c5ccc(cc5Cl)Cl | InChI = 1/C26H19Cl2N5O2/c27-20-10-11-21(22(28)14-20)23(15-33-13-12-29-16-33)30-24(34)17-6-8-19(9-7-17)26-32-31-25(35-26)18-4-2-1-3-5-18/h1-14,16,23H,15H2,(H,30,34)/t23-/m0/s1 | InChIKey = CJPLMXOWZZCYHJ-QHCPKHFHBZ | StdInChI = 1S/C26H19Cl2N5O2/c27-20-10-11-21(22(28)14-20)23(15-33-13-12-29-16-33)30-24(34)17-6-8-19(9-7-17)26-32-31-25(35-26)18-4-2-1-3-5-18/h1-14,16,23H,15H2,(H,30,34)/t23-/m0/s1 | StdInChIKey = CJPLMXOWZZCYHJ-QHCPKHFHSA-N |Section2={{Chembox Properties | C=26 | H=19 | Cl=2 | N=5 | O=2 | Appearance = | Density = | MeltingPt = | BoilingPt = | Solubility = |Section3={{Chembox Hazards | MainHazards = | FlashPt = | AutoignitionPt = }} VNI is an experimental drug for treating Chagas disease currently being studied at Vanderbilt University. The molecule acts by inhibiting Trypanosoma cruzi sterol 14α-desmethylase activity in vitro. It exhibits no toxicity in mouse cells and unlike the related compounds posaconazole and fluconazole, increasing the dose is not required to maintain anti-parasitic activity.[1][2][3]{{primary-inline|date=May 2013}} According to the researchers, "VNI cures the acute and chronic forms of Chagas disease in mice, with 100% survival and no observable side effects. Low cost (<$0.10/mg [4]), oral bioavailability, favorable pharmacokinetics, and low toxicity make this compound an exceptional candidate for clinical trials. The efficacy of VNI provides additional compelling support for efficacious antiparasitic treatment of chronic Chagas disease, further validating CYP51 as a viable drug targeting T. cruzi, and it opens a new opportunity for therapeutic cure of patients. Although widespread searches for other new drugs that target T. cruzi are surely being pursued, there are millions of patients with this debilitating illness who need immediate therapy, and VNI or a derivative might fulfill this need."[1]{{primary-inline|date=May 2013}} References1. ^1 {{Cite journal |pmid=23372180 |year=2013 |last1=Villalta |first1=F |last2=Dobish |first2=MC |last3=Nde |first3=PN |last4=Kleshchenko |first4=YY |last5=Hargrove |first5=TY |last6=Johnson |first6=CA |last7=Waterman |first7=JN |last8=Johnston |first8=MR |last9=Lepesheva |first9=GI |title=VNI Cures Acute and Chronic Experimental Chagas Disease |doi=10.1093/infdis/jit042 |journal=The Journal of Infectious Diseases |volume=208 |issue=3 |pages=504–11 |pmc=3698996}} 2. ^{{Cite journal |pmid=23504044 |year=2012 |last1=Hargrove |first1=TY |last2=Kim |first2=K |author3=de Nazaré Correia Soeiro M |last4=Da Silva |first4=CF |last5=Da Gama Jaen Batista |first5=DD |last6=Batista |first6=MM |last7= Yazlovitskaya |first7=EM |last8=Waterman |first8=MR |last9=Sulikowski |first9=GA |last10=Lepesheva |first10=GI |title=CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds |volume=2 |pages=178–186 |pmc=3596085 |journal=International journal for parasitology, drugs and drug resistance |doi=10.1016/j.ijpddr.2012.06.001}} 3. ^{{Cite journal |pmid=19923211 |year=2010 |last1=Lepesheva |first1=GI |last2=Park |first2=HW |last3=Hargrove |first3=TY |last4=Vanhollebeke |first4=B |last5=Wawrzak |first5=Z |last6=Harp |first6=JM |last7=Sundaramoorthy |first7=M |last8=Nes |first8=WD |last9=Pays |first9=E |last10=Chaudhuri |first10=M |last11=Villalta |first11=F |last12=Waterman |first12=MR |title=Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections |doi=10.1074/jbc.M109.067470 |pmc=2804335 |journal=The Journal of Biological Chemistry |volume=285 |issue=3 |pages=1773–80}} 4. ^{{cite journal | doi = 10.1021/ol303092v | title = Organocatalytic, Enantioselective Synthesis of VNI: A Robust Therapeutic Development Platform for Chagas, a Neglected Tropical Disease | year = 2012 | last1 = Dobish | first1 = Mark C. | last2 = Villalta | first2 = Fernando | last3 = Waterman | first3 = Michael R. | last4 = Lepesheva | first4 = Galina I. | last5 = Johnston | first5 = Jeffrey N. | journal = Organic Letters | volume = 14 | issue = 24 | pages = 6322–5 | pmid = 23214987 | pmc = 3528807}} 4 : Enzyme inhibitors|Chloroarenes|Oxadiazoles|Imidazoles |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。